Compare PLUS & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUS | OCS |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 1996 | N/A |
| Metric | PLUS | OCS |
|---|---|---|
| Price | $80.41 | $11.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 274.1K | ★ 1.1M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 24.20 | N/A |
| EPS | ★ 5.03 | N/A |
| Revenue | ★ $2,442,549,000.00 | N/A |
| Revenue This Year | $19.83 | $466.06 |
| Revenue Next Year | $4.36 | $479.73 |
| P/E Ratio | $15.75 | ★ N/A |
| Revenue Growth | ★ 18.07 | N/A |
| 52 Week Low | $62.11 | $10.52 |
| 52 Week High | $93.98 | $34.48 |
| Indicator | PLUS | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 26.90 |
| Support Level | $77.97 | $10.52 |
| Resistance Level | $90.93 | $21.82 |
| Average True Range (ATR) | 3.39 | 0.78 |
| MACD | -0.36 | 0.37 |
| Stochastic Oscillator | 34.39 | 45.56 |
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.